Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

59
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
59
Vaccine Production01:23

Vaccine Production

89
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
89
Vaccines01:21

Vaccines

55
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
55
Vaccinations01:51

Vaccinations

54.6K
Overview
54.6K
Cross-reactivity00:42

Cross-reactivity

34.0K
Overview
34.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Partner change, birth interval and risk of pre-eclampsia: a paradoxical triangle.

Paediatric and perinatal epidemiology·2007
Same author

Partner change and perinatal outcomes: a systematic review.

Paediatric and perinatal epidemiology·2007
Same author

A controversial tumor marker: is SM22 a proper biomarker for gastric cancer cells?

Journal of proteome research·2007
Same author

A strategy for high-throughput analysis of levosimendan and its metabolites in human plasma samples using sequential negative and positive ionization liquid chromatography/tandem mass spectrometric detection.

Rapid communications in mass spectrometry : RCM·2007
Same author

[Leukemic cell apoptosis induced by anti-human DR5 monoclonal antibody mDRA-6].

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology·2007
Same author

[Infection of intervertebral space and the interventional therapy].

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences·2007
Same journal

Combination adjuvants: clinical value and mechanisms of action.

Current opinion in virology·2026
Same journal

Editorial Overview: Immunopathogenesis in viral disease.

Current opinion in virology·2026
Same journal

Architecture and evolution of viral complement evasion.

Current opinion in virology·2026
Same journal

The HEV capsid through a dynamic lens: parallels and divergence from caliciviruses.

Current opinion in virology·2026
Same journal

When structural rationales fall short: revisiting the immunogenicity of herpesvirus prefusion and postfusion glycoprotein B.

Current opinion in virology·2026
Same journal

Beyond brain fog: viral proteins as convergent drivers of neuroinflammation and proteinopathy.

Current opinion in virology·2026
See all related articles

Related Experiment Video

Updated: Apr 14, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Lessons from hepatitis E vaccine design.

Shaowei Li1, Jun Zhang1, Ningshao Xia1

  • 1State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen 361005, China; National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Public Health, Xiamen University, Xiamen 361005, China.

Current Opinion in Virology
|April 28, 2015
PubMed
Summary
This summary is machine-generated.

Developing the first commercial hepatitis E vaccine (Hecolin) provides crucial insights for preventing hepatitis E virus (HEV) infection. Lessons learned from its antigenicity, immunogenicity, and large-scale clinical verification offer a paradigm for future vaccine design.

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.5K

Related Experiment Videos

Last Updated: Apr 14, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.5K

Area of Science:

  • Virology
  • Vaccinology
  • Public Health

Background:

  • Acute hepatitis E remains a significant global health concern, particularly in developing nations.
  • Hepatitis E virus (HEV) infection poses a substantial public health challenge, necessitating effective prevention strategies.
  • Prophylactic vaccines are considered the most viable approach for controlling HEV transmission.

Purpose of the Study:

  • To review the development process of the first commercial hepatitis E vaccine, Hecolin.
  • To elucidate the key factors contributing to the success of Hecolin.
  • To provide molecular insights for future B-cell epitope-based vaccine design.

Main Methods:

  • Review of the development and commercialization of the Hecolin vaccine.
  • Analysis of the antigenicity and immunogenicity of virus-like particle (VLP) immunogens.
  • Examination of the scalable Escherichia coli expression system.
  • Evaluation of large-scale clinical verification data.

Main Results:

  • The development of Hecolin, launched in China in 2012, demonstrated the feasibility of a commercial HEV vaccine.
  • The vaccine's success was attributed to the antigenicity and immunogenicity of VLP immunogens, coupled with a scalable production system.
  • Structural studies of the HEV capsid protein revealed insights into virus assembly and antibody neutralization.

Conclusions:

  • The Hecolin vaccine development offers valuable lessons for preventing hepatitis E virus infection.
  • Understanding HEV capsid protein structures provides a foundation for designing effective B-cell epitope-based vaccines.
  • This work establishes a paradigm for developing prophylactic vaccines against viral diseases.